Oncology

News

Final obstacles in front of Pfizer, Seagen merger fall

Pfizer is expecting to close its $43 billion acquisition of antibody-drug conjugate (ADC) pioneer Seagen tomorrow, after receiving all the required regulatory approvals fo

News

Digitised pathology resource will speed HIV cancer R&D

A collection of clinical specimens that has been gathered from people living with HIV for almost 30 years has been given a digital makeover with the help of computational

R&D

Biofidelity’s ASPYRE: The future is bright for oncology

Genomic technology company Biofidelity has announced the launch of ASPYRE-Lung reagents (RUO) for research use, marking its second product launch this year, with the aim of providing simple

News

Merck grabs late-stage oncology drug from China’s Abbisko

Germany’s Merck KGaA is paying Chinese biotech Abbisko Therapeutics $70 million upfront for rights to a drug in phase 3 testing for tenosynovial giant cell tumour (TGCT), a rare disea

News

AbbVie agrees $10.1bn deal to buy ImmunoGen

AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovar

News

CRUK charts course to solve UK’s poor cancer survival rate

Thousands of people are dying needlessly from cancer in the UK because it is lagging behind other countries in earlier detection rates, according to Cancer Research UK.

Final obstacles in front of Pfizer, Seagen merger fall

Digitised pathology resource will speed HIV cancer R&D

Biofidelity’s ASPYRE: The future is bright for oncology

Merck grabs late-stage oncology drug from China’s Abbisko

AbbVie agrees $10.1bn deal to buy ImmunoGen

CRUK charts course to solve UK’s poor cancer survival rate

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Oncology

Editor's Picks